Maxim Group Reaffirms Hold Rating for VistaGen Therapeutics (NASDAQ:VTGN)

VistaGen Therapeutics (NASDAQ:VTGN)‘s stock had its “hold” rating reiterated by investment analysts at Maxim Group in a research report issued to clients and investors on Wednesday, Marketbeat.com reports.

Other analysts also recently issued reports about the company. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a report on Wednesday. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, VistaGen Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Stock Performance

VistaGen Therapeutics stock opened at $0.74 on Wednesday. The firm has a market cap of $29.22 million, a price-to-earnings ratio of -0.39 and a beta of 0.56. VistaGen Therapeutics has a 52-week low of $0.73 and a 52-week high of $5.14. The firm has a 50 day moving average price of $4.06 and a two-hundred day moving average price of $3.29.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.16 million. As a group, equities research analysts predict that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC grew its stake in VistaGen Therapeutics by 246.4% in the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock valued at $1,052,000 after acquiring an additional 299,304 shares during the period. AdvisorShares Investments LLC raised its position in shares of VistaGen Therapeutics by 27.7% during the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock worth $406,000 after purchasing an additional 44,000 shares during the period. Bank of America Corp DE lifted its holdings in shares of VistaGen Therapeutics by 926.0% in the 3rd quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock worth $123,000 after purchasing an additional 31,279 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in VistaGen Therapeutics in the 3rd quarter valued at $39,000. Finally, Occudo Quantitative Strategies LP bought a new stake in VistaGen Therapeutics during the 3rd quarter valued at $152,000. 78.39% of the stock is owned by institutional investors and hedge funds.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.